health
April 16, 2026
Exclusive: OpenAI lobbies for expanded AI role in life sciences
Progress in life sciences has slowed dramatically — even as the toughest diseases remain unsolved.
TL;DR
- AI can accelerate drug discovery, design new tools, and automate labs, potentially compressing timelines.
- OpenAI suggests AI could find new uses for existing drugs and cut clinical-phase timelines by over 20%.
- Challenges include the slow pace of biomedical discovery, 'Eroom's Law,' and the need for greater access to medical data.
- Competitors like Amazon are also launching AI agents for drug discovery.
- No fully AI-discovered or designed drug has yet passed phase 3 trials, and AI-discovered drugs show similar failure rates in phase 2 as non-AI drugs.
- AI hallucinations and inaccuracies, though reduced, are still present, necessitating rigorous accuracy measurement and expert validation.
- OpenAI advocates for treating advanced AI as a national research resource and investing in physical infrastructure for AI use.
Continue reading the original article